Enodia Therapeutics
Enodia Therapeutics pursues first-in-class therapies for cancer, inflammatory diseases, and viral infections by targeting the translocon. It uses an AI-driven platform to design selective small molecules that block protein secretion and promote degradation of pathological proteins at their source. The company operates in biotech with a focus on early-stage research collaborations and disease targets, integrating AI with medicinal chemistry. Enodia originated from Institut Pasteur and is supported by Argobio. As it builds its pipeline, the company aims to partner with pharma to translate its translocon inhibitors to clinical use.
Enodia Therapeutics
Enodia Therapeutics pursues first-in-class therapies for cancer, inflammatory diseases, and viral infections by targeting the translocon. It uses an AI-driven platform to design selective small molecules that block protein secretion and promote degradation of pathological proteins at their source. The company operates in biotech with a focus on early-stage research collaborations and disease targets, integrating AI with medicinal chemistry. Enodia originated from Institut Pasteur and is supported by Argobio. As it builds its pipeline, the company aims to partner with pharma to translate its translocon inhibitors to clinical use.